Table 2.
Characteristics of Study Subjects
| Variable | N (87) | % | ||
|---|---|---|---|---|
| Sex | ||||
| Male | 69 | 79.3 | ||
| Female | 18 | 20.7 | ||
| Age, years | ||||
| Mean ± SD | 59.1 ± 10.2 | |||
| Specimen acquisition technique (N=87) | ||||
| Open surgery | 44 | 50.5 | ||
| Minimally-invasive biopsy | 43 | 49.5 | ||
| Transbronchial biopsy | 3 | 7.0 | ||
| Pleural biopsy | 4 | 9.3 | ||
| Bronchoscopy – forceps biopsy | 13 | 30.2 | ||
| Transthoracal core biopsy | 16 | 37.2 | ||
| Bronchoscopy – cryobiopsy | 7 | 16.3 | ||
| Year sample obtained (N=87) | ||||
| 2017 | 7 | 8.0 | ||
| 2018 | 13 | 14.9 | ||
| 2019 | 7 | 8.0 | ||
| 2020 | 1 | 1.1 | ||
| 2021 | 5 | 5.7 | ||
| 2022 | 31 | 35.6 | ||
| 2023 | 23 | 26.4 | ||
| Smoking status (N=87) | ||||
| Smoker | 43 | 49.0 | ||
| Non-smoker | 18 | 21.0 | ||
| Unknown | 26 | 30.0 | ||
| Brinkman Indeks (N=43) | ||||
| Light | 4 | 9.3 | ||
| Moderate | 18 | 41.9 | ||
| Heavy | 20 | 46.5 | ||
| Unknown | 1 | 2.3 | ||
| EGFR mutation (N=38) | ||||
| Wild type | 16 | 42.0 | ||
| Common mutation | 21 | 55.0 | ||
| Uncommon | 1 | 3.0 | ||
| NSCLC type (N=87) | ||||
| Adenocarcinoma | 55 | 63.0 | ||
| Squamous cell carcinoma | 29 | 33.0 | ||
| Other | 3 | 4.0 | ||
| Stage at diagnosis (N=70) | ||||
| IA | 3 | 4.3 | ||
| IB | 3 | 4.3 | ||
| IIA | 2 | 2.9 | ||
| IIB | 3 | 4.3 | ||
| IIIA | 9 | 12.8 | ||
| IIIB | 5 | 7.1 | ||
| IIIC | 2 | 2.9 | ||
| IVA | 37 | 52.9 | ||
| IVB | 6 | 8.6 | ||
| Performance status at diagnosis (N=87) | ||||
| 0 | 9 | 10.3 | ||
| 1 | 41 | 47.1 | ||
| 2 | 11 | 12.6 | ||
| 3 | 8 | 9.2 | ||
| 4 | 1 | 1.2 | ||
| Unknown | 17 | 19.5 | ||
*Brinkman Index light: 0-200, moderate: 201-599, heavy: ≥600; EGFR: epidermal growth factor receptor; NSCLC: non small cell lung carcinoma.